Gene expression signatures in biopsy cores as predictors of coexisting higher-grade disease in Gleason group 1 prostate cancer: Results from the Miami MAST prospective clinical trial. This is an ASCO ...
Patient characteristics and survival in primary prostate sarcomas: An analysis of the SEER database.
Heterogeneity in subgroup reporting across clinical trials assessing systemic therapies in metastatic castration resistant prostate cancer: A report from a living systematic review. Final overall ...
News Medical on MSN2d
Jumbled proteins paint a bold target on the backs of brain tumorsImmune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their ...
There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...
AZoLifeSciences on MSN1d
Immunotherapy Breakthrough Targets Jumbled Proteins in GliomaImmune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.
1Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tays Cancer Center, Tampere University, Tampere, Finland.
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Panning for Gold: The Role of ctDNA as ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback